[go: up one dir, main page]

CR20190026A - Composición vaginal que comprende una combinación de estrógeno y vitamina d - Google Patents

Composición vaginal que comprende una combinación de estrógeno y vitamina d

Info

Publication number
CR20190026A
CR20190026A CR20190026A CR20190026A CR20190026A CR 20190026 A CR20190026 A CR 20190026A CR 20190026 A CR20190026 A CR 20190026A CR 20190026 A CR20190026 A CR 20190026A CR 20190026 A CR20190026 A CR 20190026A
Authority
CR
Costa Rica
Prior art keywords
vitamin
combination
estrogen
vaginal composition
vaginal
Prior art date
Application number
CR20190026A
Other languages
English (en)
Inventor
Enrico; Colli
David F ; Archer
Original Assignee
Chemo Res S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Res S L filed Critical Chemo Res S L
Publication of CR20190026A publication Critical patent/CR20190026A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065—Diphenyl-substituted acyclic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a no a una composición vaginal que comprende una combinación de estrón-Y vitamina-D y un anánlogo de vitamina-D en una dosis diaria de (i) estrón-que corresponde a 1 µg a 100 µg de deestro-equivalente de estradiol-y (ii) vitamina-Do-anánlogo que corresponde a 7,5 µg a 100 µg de Vitamina-D-equivalencia.
CR20190026A 2016-07-22 2017-07-20 Composición vaginal que comprende una combinación de estrógeno y vitamina d CR20190026A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305941.3A EP3272333A1 (en) 2016-07-22 2016-07-22 Vaginal composition comprising a combination of estrogen and vitamin d
PCT/EP2017/068391 WO2018015503A1 (en) 2016-07-22 2017-07-20 Vaginal composition comprising a combination of estrogen and vitamin d

Publications (1)

Publication Number Publication Date
CR20190026A true CR20190026A (es) 2019-04-09

Family

ID=56561320

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190026A CR20190026A (es) 2016-07-22 2017-07-20 Composición vaginal que comprende una combinación de estrógeno y vitamina d

Country Status (10)

Country Link
US (2) US20190224213A1 (es)
EP (2) EP3272333A1 (es)
BR (1) BR112019001207A2 (es)
CL (1) CL2019000174A1 (es)
CO (1) CO2019000604A2 (es)
CR (1) CR20190026A (es)
MX (1) MX390231B (es)
NI (1) NI201900004A (es)
PH (1) PH12019500137A1 (es)
WO (1) WO2018015503A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
EP3787659A1 (en) * 2018-05-04 2021-03-10 The Procter & Gamble Company Compositions and methods for treating vaginal atrophy
WO2019213473A1 (en) 2018-05-04 2019-11-07 The Procter & Gamble Company Compositions and methods for treating vaginal dryness
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
EP4066824A1 (en) * 2021-03-31 2022-10-05 Dompe' Farmaceutici S.P.A. Combination therapy for covid-19 vaccination

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3062715A (en) 1953-11-18 1962-11-06 George S Pfaus Vaginal tablet
IE61236B1 (en) 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
US5514698A (en) 1994-03-21 1996-05-07 Ortho Pharmaceutical Corporation Antifungal vaginal cream composition
JP3705620B2 (ja) 1994-12-28 2005-10-12 帝国臓器製薬株式会社 経粘膜投与用製剤
EP0889724A1 (en) 1996-02-27 1999-01-13 Rpms Technology Limited Cox-2 selective inhibitors for managing labour and uterine contractions
DE19608423A1 (de) 1996-03-05 1997-09-11 Merck Patent Gmbh Implantate mit phasenweiser Arzneistoffabgabe
IL123813A0 (en) 1997-04-11 1998-10-30 Akzo Nobel Nv Drug delivery system for two or more active substances
US6197327B1 (en) 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
US6905701B2 (en) 1997-06-11 2005-06-14 Umd, Inc. Formulations for transmucosal vaginal delivery of bisphosphonates
US20050276836A1 (en) 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
US20040043071A1 (en) 2002-06-21 2004-03-04 Pauletti Giovanni M. Intravaginal mucosal or transmucosal delivery of antimigraine and antinausea drugs
FR2766710B1 (fr) 1997-08-04 1999-10-29 Inst Pharma De Rech Applic Et Composition pharmaceutique, comprime forme a partir de celle-ci et son utilisation comme antiseptique vaginal a action prolongee
DE19916419B4 (de) 1999-04-08 2005-06-16 Schering Ag Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
US6855703B1 (en) * 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
ATE532521T1 (de) * 2000-12-15 2011-11-15 Novo Nordisk Femcare Ag Verwendung eines östrogens bei der herstellung einer östrogenhaltigen zusammensetzung zur behandlung von atrophischer vaginitis
US7004171B2 (en) 2002-02-25 2006-02-28 Hi-Gienic Intra Vaginal Technologies Ltd. System for transvaginal drug delivery
WO2004103232A1 (en) 2003-05-15 2004-12-02 Apothecus Pharmaceutical Corp. Dissolvable vaginal deodorizing films and methods of vaginal deodorizing utilizing pliable dissolvable film
WO2005016321A1 (en) 2003-08-15 2005-02-24 Qlt Usa, Inc. Adhesive bioerodible transmucosal drug delivery system
US20050070501A1 (en) 2003-09-29 2005-03-31 New York Blood Center, Inc. Water dispersible film
US20060040904A1 (en) 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
ATE540684T1 (de) 2005-04-27 2012-01-15 Shenzhen Phlora Biotechnology Ltd Zubereitung und verfahren zur regulierung und aufrechterhaltung der vaginalen bakterienflora und der normalen acidität in der vagina
CA2640432A1 (en) 2006-01-27 2007-08-09 Duramed Pharmaceuticals, Inc. Regimens for treatment of conditions related to estrogen deficiency
CA2687310A1 (en) 2007-05-24 2008-12-04 New York Blood Center Inc. Rapidly dispersible vaginal tablet that provides a bioadhesive gel
US20080312198A1 (en) 2007-06-14 2008-12-18 Rodriguez Gustavo C Pharmaceutical products containing hormones and a 25-hydroxy vitamin d compound
DK2456421T3 (en) 2009-07-21 2017-06-06 The Population Council Inc VAGINAL RING consisting of multiple layers with gradient
CA2808276A1 (en) 2010-08-20 2012-02-23 Teva Women's Health, Inc. Intravaginal devices, methods of making, and uses thereof
CN102641548B (zh) 2011-02-18 2016-08-03 帕洛阿尔托研究中心公司 包括化学品渗透增强剂的透粘膜药物输送装置和方法
KR101785414B1 (ko) 2011-12-29 2017-10-16 라보라토리오스 안드로마코 에스.에이. 여성에서 연속 사용 피임제로서 사용될 수 있는, 멜록시캄 및 유효 성분 방출 조절제를 포함하는 질 고리
WO2013098592A1 (es) 2011-12-29 2013-07-04 Universidad De Chile Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberación del principio activo, útil para aumentar la reserva ovárica en mujeres y para aliviar síntomas asociados a la menopausia
ITMI20120867A1 (it) 2012-05-18 2013-11-19 Labomar S R L Composizione per il trattamento di lesioni.
FR3018193B1 (fr) 2014-03-10 2017-09-08 Probionov Comprime vaginal muco-adhesif a liberation prolongee
CN107073019B (zh) * 2014-03-13 2020-04-17 深圳优丽康生物技术有限公司 一种阴道用组合物与该组合物的用途
WO2016054002A1 (en) 2014-09-29 2016-04-07 Yale University Progesterone impregnated vaginal ring/pessary

Also Published As

Publication number Publication date
CL2019000174A1 (es) 2019-06-28
EP3487478A1 (en) 2019-05-29
PH12019500137A1 (en) 2019-07-29
CO2019000604A2 (es) 2019-05-21
MX390231B (es) 2025-03-20
US20210069210A1 (en) 2021-03-11
NI201900004A (es) 2019-04-29
MX2019000806A (es) 2019-06-20
US20190224213A1 (en) 2019-07-25
BR112019001207A2 (pt) 2019-04-30
US11590145B2 (en) 2023-02-28
EP3272333A1 (en) 2018-01-24
WO2018015503A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
CO2019000604A2 (es) Composición vaginal que comprende una combinación de estrógeno y vitamina d
MX2017008698A (es) Composiciones multi-suplementos.
CL2015002622A1 (es) Composiciones sinérgicas que comprenden una cepa de bacillus subtilis y un bioplaguicida
MX2022005380A (es) Composiciones que comprenden colina.
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
UY36759A (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
MX2017001512A (es) Compuestos activos hacia bromodominios.
MX372914B (es) Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
CL2017002781A1 (es) Métodos de tratamiento de enfermedad de alzheimer
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
MX2022005372A (es) Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o mas estatinas.
MX2019008917A (es) Composiciones farmaceuticas para terapia de combinacion.
MX375628B (es) Macrociclos odorizantes sutiles y amaderados.
MX385910B (es) Composiciones de fragancia que comprenden ciclohexanoato de etilo.
CL2016003023A1 (es) “compuestos derivados de (bencil-piperazin-1-il)(tetrahidrofuran-carbonil o tetrahidropiran-carbonil) sustituido, moduladores rorg; composición farmacéutica que los comprende; y su uso en el tratamiento de la esclerosis múltiple y espondilitis anquilosante”. pct
DOP2020000104A (es) Métodos de uso y composiciones que contienen dulaglutida
MX2019010330A (es) Formulaciones con mejora de la estabilidad.
MX388400B (es) Una composición de dos componentes, que comprende ácido acetilsalicílico.
BR112017018618A2 (pt) odorizante de osmanthus
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
BR112017014792A2 (pt) material em folha fumável, método de preparação de uma folha de material fumável, artigo de fumar e uso de um material em folha fumável
CL2020000586A1 (es) Moduladores de la expresión de enac.